A detailed history of Charles Schwab Investment Management Inc transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 208,391 shares of BMEA stock, worth $1.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
208,391
Previous 200,840 3.76%
Holding current value
$1.34 Million
Previous $903,000 133.0%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.23 - $10.1 $31,940 - $76,265
7,551 Added 3.76%
208,391 $2.1 Million
Q2 2024

Aug 12, 2024

BUY
$4.14 - $15.3 $90,686 - $335,146
21,905 Added 12.24%
200,840 $903,000
Q1 2024

May 08, 2024

BUY
$13.92 - $19.5 $29,760 - $41,691
2,138 Added 1.21%
178,935 $2.68 Million
Q4 2023

Feb 06, 2024

BUY
$8.37 - $19.8 $19,828 - $46,906
2,369 Added 1.36%
176,797 $2.57 Million
Q3 2023

Nov 08, 2023

BUY
$13.44 - $23.02 $1.6 Million - $2.74 Million
119,001 Added 214.7%
174,428 $2.4 Million
Q2 2023

Aug 09, 2023

BUY
$21.66 - $41.8 $1.03 Million - $2 Million
47,747 Added 621.71%
55,427 $1.22 Million
Q1 2023

May 11, 2023

BUY
$6.8 - $32.35 $52,224 - $248,448
7,680 New
7,680 $238,000
Q2 2022

Aug 15, 2022

SELL
$3.0 - $12.03 $159,840 - $640,958
-53,280 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$4.39 - $9.03 $11,725 - $24,119
2,671 Added 5.28%
53,280 $238,000
Q4 2021

Feb 11, 2022

BUY
$7.22 - $12.72 $206,990 - $364,669
28,669 Added 130.67%
50,609 $378,000
Q2 2021

Aug 16, 2021

BUY
$13.65 - $20.93 $299,481 - $459,204
21,940 New
21,940 $343,000

Others Institutions Holding BMEA

About Biomea Fusion, Inc.


  • Ticker BMEA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,290,600
  • Market Cap $189M
  • Description
  • Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...
More about BMEA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.